Activation of the unfolded protein response follows induction of endoplasmic reticulum (ER) stress, resulting in widespread inhibition of protein expression. FLIP protein is particularly sensitive to stresses that perturb protein translation; as such, a reduction in FLIP is likely an early outcome of ER stress. Due to the anti-apoptotic role of FLIP, it is anticipated that potential decreases in FLIP would bring about an increase in sensitivity to death receptor stimuli and anoikis, a form of anchorage-dependent cell death. It was hypothesized that induction of ER stress results in downregulation of FLIP expression, resulting in sensitization of resistant tumour cells to death receptor stimuli and anoikis. From this hypothesis, it was determined that induction of ER stress through treatment of cells with brefeldin sensitized tumour cells to Fas-mediated cell death and anoikis. Moreover, over-expression of FLIP appeared to protect against ER stress-induced sensitization to cell death.

Activation of the unfolded protein response follows induction of endoplasmic reticulum (ER) stress, resulting in widespread inhibition of protein expression. FLIP protein is particularly sensitive to stresses that perturb protein translation; as such, a reduction in FLIP is likely an early outcome of ER stress. Due to the anti-apoptotic role of FLIP, it is anticipated that potential decreases in FLIP would bring about an increase in sensitivity to death receptor stimuli and anoikis, a form of anchorage-dependent cell death. It was hypothesized that induction of ER stress results in downregulation of FLIP expression, resulting in sensitization of resistant tumour cells to death receptor stimuli and anoikis. From this hypothesis, it was determined that induction of ER stress through treatment of cells with brefeldin sensitized tumour cells to Fas-mediated cell death and anoikis. Moreover, over-expression of FLIP appeared to protect against ER stress-induced sensitization to cell death.

Células apresentadoras de antígeno (APCs) controlam as respostas de linfócitos T por múltiplos mecanismos, que incluem a expressão de moléculas co-estimuladoras, a produção de citocinas e outros mediadores. Estes mecanismos exercem influência não só na proliferação, diferenciação e polarização dos linfócitos T, mas também interferem na sobrevivência destas células. No presente trabalho, foi demonstrado que fator(es) solúvel(eis) produzido(s) por APCs ativadas via receptores do tipo Toll (TLRs) suprimem a morte induzida por ativação (AICD) de linfócitos T. Este efeito foi observado em APCs não estimuladas, porém foi significativamente maior após estimulação das APCs com lipopolissacarídeo (LPS). Através do uso de diferentes camundongos nocautes, foi mostrado que a produção do fator protetor induzida por LPS é dependente da via de TLR4/MyD88 e independente de TLR2 e CD14. Este fator foi identificado como prostaglandina E2 (PGE2) e foi demonstrado que os sobrenadantes derivados de APC e a PGE2 sintética bloqueiam a expressão de CD95L em linfócitos T estimulados via TCR/CD3. A inibição da expressão de CD95L reduz tanto a AICD como a morte de macrófagos, alvos do ataque citotóxico dos linfócitos T ativados. Foi demonstrado também que, ao invés de bloquear a via do CD95, a PGE2 potencializa a morte induzida por anticorpos anti-CD95 agonistas. Os receptores de PGE2, EP2 e EP4, parecem ser os responsáveis por mediar os efeitos supressores da PGE2 na AICD, já que a estimulação farmacológica destes receptores mimetiza o efeito protetor da PGE2 e seus respectivos antagonistas interferem com a proteção conferida pelos sobrenadantes de APCs e pela PGE2 sintética. A ativação do EP2 e do EP4 age sinergicamente na ativação das vias dependentes da PKA e de EPAC, que contribuem para a inibição da AICD. Por fim, a ativação dos principais fatores de transcrição envolvidos com a expressão de CD95L (NFAT, AP-1 e NF-kB) não é bloqueada por PGE2. Por outro lado, PGE2 induziu a expressão de ICER, um repressor transcripcional, através da ativação de CREB. Em conjunto, estes resultados indicam que as APCs podem modular os níveis de expressão de CD95L através da secreção de PGE2 em resposta ao LPS, através de uma via dependente de TLR4 e MyD88, com conseqüências tanto para a morte de linfócitos T quanto para a sua própria sobrevivência. / Antigen-presenting cells (APCs) control T-cell responses by multiple mechanisms, including the expression of co-stimulatory molecules and the production of cytokines and other mediators that control T-cell proliferation, survival and differentiation. In this present work, it was demonstrated that soluble factor(s) produced by Toll-like receptor (TLR)-activated APCs suppress activation-induced cell death (AICD). This effect was observed in non-stimulated APCs, but it was significantly increased after lipopolysaccharide (LPS) treatment. Using different KO mice, it was found that the LPS-induced protective factor is dependent on TLR4/MyD88 and independent of TLR2 and CD14. The protective factor was identified as prostaglandin E2 (PGE2) and it was shown that both APC-derived supernatants and PGE2 prevented CD95L upregulation in T cells in response to TCR/CD3 stimulation, thereby avoiding both AICD and activated T cell killing of target macrophages. It was also demonstrated that instead of blocking CD95 pathway, PGE2 enhanced T cell death induced by agonistic anti-CD95 antibodies. The PGE2 receptors, EP2 and EP4, appear to be involved in AICD suppression since pharmacological stimulation of these receptors mimics the protective effect on T cells and their respective antagonists interfere with the protection induced by either APCs derived or synthetic PGE2. The engagement of EP2 and EP4 synergistically activates protein kinase A (PKA) and exchange protein directly activated by cAMP pathways to prevent AICD. Finally, the activation of the main transcription factors involved in CD95L expression (NFAT, AP-1 and NF-kB) is not avoided by PGE2. On the other hand, PGE2 induces the expression of ICER, a transcriptional repressor of CD95L, through CREB activation. Taken together, these results indicate that APCs can regulate T-cell levels of CD95L by releasing PGE2 in response to LPS through a TLR4/MyD88-dependent pathway, with consequences for both T cell and their own survival.

Renal Cell Carcinoma (RCC) has low 5 year survival rate and is resistant to radiation and chemotherapy. Phenethyl Isothiocyanate (PEITC) is a naturally occurring phytochemical that has a variety of anti-cancer properties. Here we explore two anti-cancer properties of PEITC: induction of apoptosis and induction of cell cycle arrest in RCC cells and the underlying mechanisms. We used two human RCC cell lines Caki-1 and Caki-2. Survival and cell proliferation was assayed using Calcein AM. Annexin V staining was used to measure apoptosis. Caspase-3/7 induction was measured using a fluorescent substrate. Cell cycle was studied using Propidium Iodide staining. DNA damage was determined using phospho [gamma]-H2AX antibody. Protein expression and phosphorylation was determined using immunoblotting. PEITC significantly reduced survival of Caki-1 and Caki-2 cells and inhibited their proliferation as determined by Calcein AM. 15 and 20 [mu]M PEITC induced apoptosis in both cell lines and induced caspase-3/7 activity. Western blot analysis revealed caspase-8, caspase-9 and Bid cleavage as well as upregulation of the death receptors Fas and DR5. Lower doses (up to 10 [mu]M) arrested Caki-1 cells in G2/M phase, and this was associated with increased p38 and MK2 (Thr334) phosphorylation. The p38 inhibitor SB203850 inhibited this G2 arrest induced by PEITC. 15 and 20 [mu]M PEITC treatment resulted in increased [gamma]-H2AX phosphorylation suggesting DNA damage, but this was completely blocked by caspase inhibitor. In summary, our study shows that PEITC induces apoptosis in Caki-1 and Caki-2 cells by upregulating Fas and DR5 and activating the downstream apoptosis cascade. PEITC does not cause direct DNA damage to the cells; the observed DNA damage is a result of the apoptotic process and is blocked by caspase inhibitor. PEITC induces G2/M arrest in Caki-1 cells and the mechanism involves p38 phosphorylation which activates MK2. Inducing cell cycle arrest and apoptosis may play an important role in the anti-cancer properties of PEITC. Fully understanding the mechanism by which PEITC induces apoptosis and cell cycle arrest in RCC cells may lead to development of novel chemotherapeutic drugs against RCC. / text

Células apresentadoras de antígeno (APCs) controlam as respostas de linfócitos T por múltiplos mecanismos, que incluem a expressão de moléculas co-estimuladoras, a produção de citocinas e outros mediadores. Estes mecanismos exercem influência não só na proliferação, diferenciação e polarização dos linfócitos T, mas também interferem na sobrevivência destas células. No presente trabalho, foi demonstrado que fator(es) solúvel(eis) produzido(s) por APCs ativadas via receptores do tipo Toll (TLRs) suprimem a morte induzida por ativação (AICD) de linfócitos T. Este efeito foi observado em APCs não estimuladas, porém foi significativamente maior após estimulação das APCs com lipopolissacarídeo (LPS). Através do uso de diferentes camundongos nocautes, foi mostrado que a produção do fator protetor induzida por LPS é dependente da via de TLR4/MyD88 e independente de TLR2 e CD14. Este fator foi identificado como prostaglandina E2 (PGE2) e foi demonstrado que os sobrenadantes derivados de APC e a PGE2 sintética bloqueiam a expressão de CD95L em linfócitos T estimulados via TCR/CD3. A inibição da expressão de CD95L reduz tanto a AICD como a morte de macrófagos, alvos do ataque citotóxico dos linfócitos T ativados. Foi demonstrado também que, ao invés de bloquear a via do CD95, a PGE2 potencializa a morte induzida por anticorpos anti-CD95 agonistas. Os receptores de PGE2, EP2 e EP4, parecem ser os responsáveis por mediar os efeitos supressores da PGE2 na AICD, já que a estimulação farmacológica destes receptores mimetiza o efeito protetor da PGE2 e seus respectivos antagonistas interferem com a proteção conferida pelos sobrenadantes de APCs e pela PGE2 sintética. A ativação do EP2 e do EP4 age sinergicamente na ativação das vias dependentes da PKA e de EPAC, que contribuem para a inibição da AICD. Por fim, a ativação dos principais fatores de transcrição envolvidos com a expressão de CD95L (NFAT, AP-1 e NF-kB) não é bloqueada por PGE2. Por outro lado, PGE2 induziu a expressão de ICER, um repressor transcripcional, através da ativação de CREB. Em conjunto, estes resultados indicam que as APCs podem modular os níveis de expressão de CD95L através da secreção de PGE2 em resposta ao LPS, através de uma via dependente de TLR4 e MyD88, com conseqüências tanto para a morte de linfócitos T quanto para a sua própria sobrevivência. / Antigen-presenting cells (APCs) control T-cell responses by multiple mechanisms, including the expression of co-stimulatory molecules and the production of cytokines and other mediators that control T-cell proliferation, survival and differentiation. In this present work, it was demonstrated that soluble factor(s) produced by Toll-like receptor (TLR)-activated APCs suppress activation-induced cell death (AICD). This effect was observed in non-stimulated APCs, but it was significantly increased after lipopolysaccharide (LPS) treatment. Using different KO mice, it was found that the LPS-induced protective factor is dependent on TLR4/MyD88 and independent of TLR2 and CD14. The protective factor was identified as prostaglandin E2 (PGE2) and it was shown that both APC-derived supernatants and PGE2 prevented CD95L upregulation in T cells in response to TCR/CD3 stimulation, thereby avoiding both AICD and activated T cell killing of target macrophages. It was also demonstrated that instead of blocking CD95 pathway, PGE2 enhanced T cell death induced by agonistic anti-CD95 antibodies. The PGE2 receptors, EP2 and EP4, appear to be involved in AICD suppression since pharmacological stimulation of these receptors mimics the protective effect on T cells and their respective antagonists interfere with the protection induced by either APCs derived or synthetic PGE2. The engagement of EP2 and EP4 synergistically activates protein kinase A (PKA) and exchange protein directly activated by cAMP pathways to prevent AICD. Finally, the activation of the main transcription factors involved in CD95L expression (NFAT, AP-1 and NF-kB) is not avoided by PGE2. On the other hand, PGE2 induces the expression of ICER, a transcriptional repressor of CD95L, through CREB activation. Taken together, these results indicate that APCs can regulate T-cell levels of CD95L by releasing PGE2 in response to LPS through a TLR4/MyD88-dependent pathway, with consequences for both T cell and their own survival.

No description available.

Breast cancer is the second leading cause of death due to cancer in women. A number of effective therapeutic strategies have been implemented in clinics to cope with the disease yet recurrent disease and toxicity reduce their effectiveness. Hence, there is a need to identify and develop more effective therapies with reduced toxic side effects to improve overall survival rates. This dissertation investigates the mechanisms of action of two natural forms of vitamin E and a cholesterol lowering drug, simvastatin, as a therapeutic strategy in human breast cancer cells. Vitamin E in nature consists of eight distinct forms which are fat soluble small lipids. Until recently, vitamin E was known as a potent antioxidant but emerging work suggests they may be resourceful agents in managing a number of chronic diseases including cancer. Anticancer properties of vitamin E have been identified to be limited to the γ- and δ- forms of both tocopherols and tocotrienols. Gamma-tocopherol ([gamma]T) and gamma-tocotrienol ([gamma]T3) have both already been identified to induce death receptor 5 (DR5) mediated apoptosis in breast cancer cells. Studies here show that similar to [gamma]T3, [gamma]T induced DR5 activation is mediated by c-Jun N-terminal kinase/C/EBP homologous protein (JNK/CHOP) proapoptotic axis which in part contributed to [gamma]T mediated dowregulation of c-FLIP, Bcl-2 and Survivin. Also, both agents activate de novo ceramide synthesis pathway which induces JNK/CHOP/DR5 proapoptotic axis and downregulates antiapoptotic factors FLICE inhibitory protein (c-FLIP), B-cell lymphoma 2 (Bcl-2) and Survivin leading to apoptosis. Simvastatin (SVA) has been identified to display pleiotropic effects including anticancer effects but mechanisms responsible for these actions have yet to be fully understood. In this dissertation, it was observed that simvastatin induced apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 proapoptotic axis and down regulation of antiapoptotic factors c-FLIP and Survivin which are in part dependent on JNK/CHOP/DR5 axis. The anticancer effects mediated by simvastatin can be reversed by exogenously added mevalonate and geranylgeranyl pyrophosphate (GGPP), implicating the blockage of mevalonate as a key event. Furthermore, work has been done to understand the factors responsible for drug resistance and identify therapeutic strategies to counteract the same. It was observed that development of drug resistance was associated with an increase in the percentage of tumor initiating cells (TICs) in both tamoxifen and Adriamycin resistant cells compared to their parental counterparts which was accompanied by an increase in phosphorylated form of Signal transducer and activator of transcription 3 (Stat3) proteins as well as its downstream mediators c-Myc, cyclin D1, Bcl-xL and Survivin. Inhibition of Stat3 demonstrated that Stat3 and its downstream mediators play an important role in regulation of TICs in drug resistant breast cancer. Moreover, SVA, [gamma]T3 and combination of SVA+[gamma]T3 has been observed to target TICs in drug resistant human breast cancer cells and downregulate Stat3 as well as its downstream mediators making it an attractive agent to overcome drug resistance. From the data presented here, the mechanisms responsible for the anticancer actions of [gamma]T, [gamma]T3 and SVA have been better understood, providing the necessary rationale to test these agents by themselves or in combination in pre-clinical models. / text

MicroRNAs (miRNAs) sind endogenene kurze RNA-Moleküle, die zentrale Aufgaben bei der Regulation der eukaryotischen Zellhomöostase erfüllen. MiRNAs wurden bereits als potente Immunregulatoren beschrieben. Trotz dieser Erkenntnisse blieb die Rolle dieser kurzen RNA Moleküle in Infektionen mit Mycobacterium tuberculosis weitgehend unerforscht. Im Rahmen dieser Arbeit wurde ein miRNA-Expressionsprofil von Makrophagen generiert, die mit Mycobacterium tuberculosis infiziert waren. Dies ermöglichte die Identifizierung von miRNAs, welche bei der Infektion differenziell reguliert waren. Anhand eines ex-vivo-Modells von Todesrezeptor-induzierter Apoptose konnte gezeigt werden, dass miRNA-133b apoptoseresitente Zellen empfindlich gegen Tumornekrosefaktor-alpha (TNFalpha), TNF-related apoptosis-inducing ligand (TRAIL) oder CD95 ligand (Fas/APO1 ligand) induzierte Zytotoxizität machte. Eine umfassende Studie führte zur Identifizierung der anti-apoptotischen Proteine Fas apoptosis inhibitory molecule (FAIM) und glutathione-S-transferase pi (GSTP1) als direkte Zielgene für miRNA-133b. Desweiteren zeigte sich die Expression von Osteoprotegerin (OPG) und Fettsäuresynthase (FASN), als miRNA-133b abhängig. Dies unterstrich die pleiotrope Art der pro-apoptotischen Aktivität dieser miRNA. Die Expression von miRNA-133b wurde durch Mitglieder der Toll-like Rezeptor (TLR)-Familie aktiviert. MiRNA-133b Transfektion führte zu einer verstärkten Aktivierung des Transkriptionsfaktors nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB). Diese resultierte in erhöhten Mengen an Interleukinen 6 und 8 (IL6/8). Diese Ergebnisse stellen die erste detaillierte Charakterisierung von miRNA-133b im Zusammenhang der Todesrezeptor-vermittelten Apoptose und der angeborenen Immunität dar. Die erforschten molekularen Wechselwirkungen ergänzen und bereichern das Verständnis über die regulatorischen molekularen Mechanismen, die mit der Tumorentstehung und Entzündung verbunden sind. / MicroRNAs (miRNAs) are endogenous short RNA molecules which perform essential tasks in the regulation of eukaryotic cell homeostasis. During the past few years miRNAs have emerged as very potent immune regulators. Despite the consequences of this discovery for our understanding of immune response regulation hitherto virtually nothing is known about miRNA function during innate immunity to Mycobacterium tuberculosis. Herein, a miRNA expression profile of human macrophages infected with Mycobacterium tuberculosis was generated. This led to the identification of miRNAs being differentially regulated during infection. By using an experimental ex-vivo model of death receptor (DR)-induced apoptosis it could be demonstrated that miRNA-133b rendered apoptosis-resistant cells sensitive to tumor necrosis factor-alpha (TNFalpha)-, TNF-related apoptosis-inducing ligand (TRAIL)- or CD95 ligand (Fas/APO1 ligand)-activated cytotoxicity. Comprehensive analysis led to the discovery of the anti-apoptotic proteins Fas apoptosis inhibitory molecule (FAIM) and glutathione-S-transferase pi (GSTP1) as direct miRNA-133b targets. Moreover, underlining the pleiotropic and synergistic nature of miRNA activity, the expression of osteoprotegerin (OPG) and fatty acid synthase (FASN) could be further proven as miRNA-133b dependent. Expression of miRNA-133b increased following innate immune activation by members of the Toll-like receptor (TLR) family. MiRNA-133b enhanced the activity of the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB). This translated into increased levels of the pro-inflammatory interleukins 6 and 8 (IL6/8). The results presented in this work represent the first detailed characterization of miRNA-133b in the context of DR-mediated apoptosis and innate immunity. The molecular interactions dissected herein improve the understanding of the regulatory processes associated with tumorigenesis and the immune response.